Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surge
Publishing timestamp: 2023-10-17 13:29:32
Summary
Johnson & Johnson reported better-than-expected earnings and revenue for the third quarter, and raised its full-year guidance. Sales in the pharmaceutical and medical devices businesses surged, marking the company's first quarterly results since its separation from consumer health spinoff Kenvue. However, there are challenges such as declining sales of certain drugs and ongoing lawsuits related to talc-based products. J&J's stock fell slightly after the announcement.
Sentiment: MIXED
Tickers: ABBV, JNJ, UNDEFINED,
Keywords: kenvue inc, abbvie inc, breaking news, johnson & johnson, business news, joe biden, health care industry, breaking news: earnings, biotechnology, business, earnings, pharmaceuticals, dividends, biotech and pharmaceuticals,
Source: https://www.cnbc.com/2023/10/17/johnson-johnson-jnj-q3-earnings-report-2023.html